SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Mylan Labs
MYL 15.860.0%Nov 19 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Christopher Nicora who wrote (269)3/23/1998 3:16:00 PM
From: David Lawrence  Read Replies (1) of 384
 
PITTSBURGH--(BUSINESS WIRE)--March 23, 1998--Mylan Laboratories
Inc. (NYSE:MYL) announced today that it has received an approval
from the Food and Drug Administration to manufacture and market
Diltiazem Hydrochloride Extended Release capsules in 120 MG, 180 MG
and 240 MG strengths.

This calcium channel blocker is the generic equivalent of
Watson's Dilacor XR(R) and is used for the treatment of
hypertension.

The product will be manufactured in Mylan's sustained release
facility in Morgantown, W.V.

Shipment of Diltiazem HCl ER will begin immediately.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News